# Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00129831** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 6 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** QAB149

## Key facts

- **NCT ID:** NCT00129831
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2005-09
- **Final completion:** 2005-09
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2011-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00129831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00129831, "Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00129831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*